Fig. 2From: Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective studyKaplan-Meier estimates of progression-free survival 1 (PFS1). A PFS1 in 120 patients. B PFS1 in patients with PD-L1 TPS < 1%. C PFS1 in patients with PD-L1 TPS 1–49%. D PFS1 in patients with PD-L1 TPS ≥50%Back to article page